Actively Recruiting
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Led by University of Alabama at Birmingham · Updated on 2025-07-11
240
Participants Needed
2
Research Sites
247 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.
CONDITIONS
Official Title
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be physically healthy
- Willing and able to provide informed consent (if under 18, parent or guardian consent is required)
- For MDD group: definite diagnosis according to DSM-5
- For MDD group: Children's Depression Rating Scale-Revised (CDRS-R) score of 30 or higher
- For suicidal ideation group: Columbia Suicide Severity Rating Scale (C-SSRS) score of 4 or higher in the last two weeks
- For suicide attempt group: suicide attempt in the previous two weeks requiring medical attention and showing at least medium intent on the Suicide Intent Scale
- For non-psychiatric controls: no history of major mental illness (excluding specific phobia) or substance use disorder
You will not qualify if you...
- Pregnancy or lactation
- Post-partum state within 2 months of delivery or miscarriage
- Risk of homicide as assessed by clinical interview
- Lifetime history of psychotic disorder
- Alcohol or drug use disorder (except nicotine/caffeine) within the last month
- Use of hallucinogens (except cannabis), including phencyclidine, in the last month
- Bipolar disorder
- Pervasive developmental disorder
- Cognitive disorder
- DSM-5 paranoid, schizoid, or schizotypal personality disorders (other personality disorders allowed if MDD criteria met)
- Anorexia nervosa
- Recent myocardial infarction or unstable angina
- Active cancer in past 6 months
- Immunosuppressive or corticosteroid therapy in last month
- Chemotherapy in last 6 months
- Head injury or loss of consciousness in last 6 months
- Use of hallucinogens (except cannabis), methamphetamine, or cocaine in last 2 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
UAB Huntsville Regional Medical Campus
Huntsville, Alabama, United States, 35294
Actively Recruiting
Research Team
A
Allison Stewart, MA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here